Maravai LifeSciences Market Sentiment

Maravai LifeSciences Holdings Inc

MRVINASDAQ

Trade with Public

$7.32

0.253.54%

마지막 업데이트: Oct 23, 4:00 PM

개요 뉴스 실적 전망 이벤트 목표가 재무심리지분 현황 비교 옵션 주식 보고서

실적: Q3 2026 실적이 수 11월 4th에 시장 마감 후 11일 후 후에 발표됩니다.

Maravai LifeSciences Market Sentiment - Benzinga

Maravai LifeSciences Market Sentiment

Market sentiment signals for Maravai LifeSciences (MRVI): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 11.0% short float

Options Flow▲ 0.03 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

12 analysts

Options Flow (P/C)

0.03

More calls — Bullish

58 calls · 2 puts

Avg Consensus PT

-19.1%

Highest Price Target

$10

+36.6%

Stifel

Lowest Price Target

-72.7%

Baird

Short Interest

11.0%

Rising — Bearish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Sep 9, 2026	UBS	Dan Brennan—	+9.3%	$3 → $8	Maintained	Neutral
Aug 7, 2026	Wells Fargo	Evan Stampler—	-11.2%	$6 → $7	Maintained	Overweight
May 8, 2026	Wells Fargo	Brandon Couillard—	-24.9%	$5 → $6	Maintained	Overweight
Dec 15, 2025	Wells Fargo	Brandon Couillard—	-38.5%	$4 → $5	Maintained	Overweight
Aug 12, 2025	Craig-Hallum	Christian Schwab—	-31.7%	$10 → $5	Maintained	Buy
Aug 12, 2025	RBC Capital	Conor McNamara—	-31.7%	$7 → $5	Maintained	Outperform
May 13, 2025	Craig-Hallum	Christian Schwab—	+36.6%	$12 → $10	Maintained	Buy
May 13, 2025	Baird	Catherine Schulte—	-72.7%	$3 → $2	Maintained	Neutral
Mar 25, 2025	Morgan Stanley	Tejas Savant—	-31.7%	$7 → $5	Maintained	Equal-Weight
Mar 21, 2025	UBS	Dan Brennan—	-65.8%	$8 → $3	Maintained	Neutral
Mar 3, 2025	B of A Securities	Michael Ryskin—	+9.3%	$9 → $8	Maintained	Buy
Feb 26, 2025	Baird	Catherine Schulte—	-59.0%	$9 → $3	Downgrade	Outperform→Neutral
Dec 5, 2024	Goldman Sachs	Matthew Sykes—	-41.9%	$7 → $4	Downgrade	Neutral→Sell
Nov 14, 2024	Wolfe Research	Doug Schenkel—	—	—	Initiate	Peer Perform
Nov 8, 2024	RBC Capital	Conor McNamara—	+77.6%	$17 → $13	Maintained	Outperform
Nov 8, 2024	William Blair	Matt Larew—	—	—	Downgrade	Outperform→Market Perform
Nov 8, 2024	Baird	Catherine Schulte—	+23.0%	$10 → $9	Maintained	Outperform
Oct 8, 2024	Goldman Sachs	Matthew Sykes—	-4.4%	$8 → $7	Maintained	Neutral
Aug 27, 2024	Wells Fargo	Brandon Couillard—	+36.6%	$10	Initiate	Overweight
Aug 16, 2024	RBC Capital	Conor McNamara—	+104.9%	$15 → $15	Maintained	Outperform
Aug 13, 2024	Morgan Stanley	Tejas Savant—	+36.6%	$11 → $10	Downgrade	Overweight→Equal-Weight
Aug 8, 2024	Goldman Sachs	Matthew Sykes—	+9.3%	$7 → $8	Maintained	Neutral
Aug 8, 2024	UBS	Dan Brennan—	+50.3%	$9 → $11	Maintained	Neutral
Jul 9, 2024	Goldman Sachs	Matthew Sykes—	-4.4%	$8 → $7	Maintained	Neutral
May 9, 2024	Baird	Catherine Schulte—	+36.6%	$8 → $10	Maintained	Outperform